NOVAICOS Srls works on innovative solutions against bone erosion, with particular focus on osteoporosis, the aim is to deveope new compounds active in inhibiting bone resorption.

      The problem

      Despite existing therapies, the risk of tumor progression is still high, and innovative and highly effective novel treatments are required, with a better control over side effects.

      The innovative solution

      Novaicos develops new drugs able to inhibit tumor growth, metastasis dissemination, and osteolytic tumours. Novaicos carrying out experiments for the use of ICOS-Fc in nanoformulations for the treatment of tumor growth and related metastases. Novaicos addresses the thematic challenge of promoting innovation to improve cancer therapies and offering new solutions for the growing market of biological drugs. Biomaterials will allow the design of nanostructured and functionalized solutions to treat cancer. [continue]

      The landscape

      National expenditures for cancer care will increase by at least 27% in the last ten years because of aging and growing population. Novaicos’ drugs are effective in tumors decreasing burden and metastases, thus may be potentially used to treat also patients with osteolytic bone metastatic cancer. Therapeutic monoclonal antibodies are now approved in many countries as a valuable pharmacological strategy. Encouraging results obtained by this research project, together with the safety of the marketed drug delivery system employed, allow to foresee a good transferability to the human setting.

      Development

      Riproduci video

      Target

      Development of new molecules active on bone resorption in different osteolytic diseases as osteoporosis and bone metastases. The first patented molecule is ICOS-Fc. ICOS-Fc is active in osteoporosis and osteopenia with possible development in the fields of autoimmunity and oncology.

      Research & Development Development of new molecules active on bone resorption in different osteolytic diseases as osteoporosis and bone metastases. The first patented molecule is ICOS-Fc. ICOS-Fc is active in osteoporosis and osteopenia with possible development in the fields of autoimmunity and oncology.
      Patrizia D’Amelio, MD,PhD
      Clinical Area Manager
      Development of new formulation Novaicos is working on different formulation of ICOS-Fc as the use of ICOS-Fc encapsuled in nanoparticles decorated or not with biphosphonates for targeting to the bone tissue.
      Elena Boggio, PhD, CTO
      Lab coordinator.
      Needs
      Research for investors and industrial partners for the development of the research and clinical phase studies.
      Maurizio Michele Zuzzaro.
      Financial Strategist
      dianzani_800x500
      Riproduci video

      Socio Economic A socio-economic burden Osteoporosis is the most frequent bone metabolic disease in the world,
      bone osteoporotic fractures severely affect the
      quality of life of patients and represent a socio-economic burden.
      Mission Mission NOVAICOS Srls works on innovative solutions against bone
      erosion, with particular focus on osteoporosis, the aim is to
      deveope new compounds active in inhibiting bone resorption.
      Innovation The innovation Novaicos Srls deveolped an immunonogiacal
      approact for osteoporosis treatment,
      effective both in vitro and in vivo and able to
      restore bone structure
      ICOS-Fc ICOS-Fc features Biologic and biocompatible
      Do not alter bone cells life span
      Without collaterl effects
      Efficacy proved in vitro and in vivo in mice

      Video & Docs

      Giotto

      Giotto scientific